TRIPOD Checklist: Prediction Model Development and Validation

Section	Item		Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract					
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Page 1 Line Number 1-2	Title
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome,statistical analysis, results, and conclusions.	Page 1-2 Line Number 17--38	Abstract
Introduction					
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Page 2-3 Line Number 42--68	Introduction
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	Page 3 Line Number 69--80	Introduction
Methods					
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation datasets, ifapplicable.	Page 4-5 Line Number 84--96	Data and patient samples Extraction
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Page 4-5 Line Number 84--96	Data and patient samples Extraction
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	N	N
	5b	D;V	Describe eligibility criteria for participants.	Page 4-5 Line Number 87--96	Data and patient samples Extraction
	5c	D;V	Give details of treatments received, if relevant.	N	N
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Page 5-6 Line Number 103--110	Construction of a prognosis-predicting model
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	1.Page 5 Line Number 98--101	1.GO and KEGG pathway enrichment analysis

				2.Page 6 Line Number 112--117 3.Page 6 Line Number 118--121 4.Page 6 Line Number 123--126 5.Page 7 Line Number 128--132	2.Drug sensitivity analysis 3.Infiltrating immune cells analysis 4.Gene set variance analysis (GSVA) 5.Gene set enrichment analysis (GSEA)
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Page 7 Line Number 134--136	Random Survival Forest (RSF)
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	N	N
Sample size	8	D;V	Explain how the study size was arrived at.	Page 4 Line Number 84--85	Data and patient samples Extraction

Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Page 5 Line Number 94--96	Data and patient samples Extraction
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	Page 7 Line Number 138--140	Statistical Analysis
	10b	D	Specify type of model, all model-building procedures (including any predictorselection),and method for internal validation.	Page 7 Line Number 138--140	Statistical Analysis
	10c	V	For validation, describe how the predictions were calculated.	Page 7 Line Number 138--140	Statistical Analysis
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Page 7 Line Number 138--140	Statistical Analysis
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	N	N
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	N	N
Development vs. validation	12	V	For validation, identify any differences from the development data insetting, eligibility criteria, outcome, and predictors.	N	N
Results					
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Page 7-8 Line Number 144--149	DEGs for bone metastasis in BRCA
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Page 7-8 Line Number 144--149	DEGs for bone metastasis in BRCA
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Page 7-8 Line Number 144--149	DEGs for bone metastasis in BRCA
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	Page 8-9 Line Number 151--171	Construction of prognostic model for BRCA
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	Page 9-10 Line Number 179--200	Multi-omics analysis of clinical predictive value of the prognostic model for BRCA
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Page 10-11 Line Number 202--210	Robust analysis of the prognostic model for BRCA
	15b	D	Explain how to the use the prediction model.	Page 7 Line Number 182-202	Construction of prognostic model of BRCA.
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	Page 11 Line Number 212--219	independent prognostic factor
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	Page 13 Line Number 251--256	Identification of key

					genes via Random survival forest (RSF) analysis
Discussion					
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	N	N

Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	Page 14-17 Line Number 270--347	Discussion
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	Page 14-17 Line Number 270--347	Discussion
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	Page 14-17 Line Number 270--347	Discussion
Other information					
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and datasets.	N	N
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	Page 18 Line Number 365--366	Funding

* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article information: https://dx.doi.org/10.21037/tcr-23-1881
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.